Abstract: The present invention provides methods for screening and identifying compounds that affect the metabolism of fatty acids and fatty acid derivatives, and thus for compounds that possess anti-diabetic as well as anti-obesity properties and possess the ability to affect the levels of chylomicrons, triacylglycerols, cholesterols, and fatty acids in a patient. Kits and compositions for screening and identifying such compounds are also provided. The invention is predicated on the identification of a physiological receptor for free fatty acids and anti-diabetic and anti-obesity drugs.

Abstract: A full-length cDNA encoding a 352-amino-acid protein contains seven regions of hydrophobic amino acids representing membrane-spanning domains of a heptahelix receptor, tentatively named CMKRL1. It shows nearly 30% overall identity with the c5a anaphylatoxin receptors and similar degree of homology with other chemoattractant receptors. Receptor expression was shown in lymphoid cells and tissues. The receptor and antibodies that recognize the receptor are useful for detecting Burkitt's lymphoma and for lowering leukotriene B4 levels in a mammal.

Abstract: The present invention provides methods for screening and identifying compounds that affect the metabolism of fatty acids and fatty acid derivatives, and thus for compounds that possess anti-diabetic as well as anti-obesity properties and possess the ability to affect the levels of chylomicrons, triacylglycerols, cholesterols, and fatty acids in a patient. Kits and compositions for screening and identifying such compounds are also provided. The invention is predicated on the identification of a physiological receptor for free fatty acids and anti-diabetic and anti-obesity drugs.

Abstract: A full-length cDNA encoding a 352-amino-acid protein contains seven regions of hydrophobic amino acids representing membrane-spanning domains of a heptahelix receptor, tentatively named CMKRL1. It shows nearly 30% overall identity with the c5a anaphylatoxin receptors and similar degree of homology with other chemoattractant receptors. Receptor expression was shown in lymphoid cells and tissues. The receptor and antibodies that recognize the receptor are useful for detecting Burkitt's lymphoma and for lowering leukotriene B4 levels in a mammal.

Abstract: A full-length cDNA encoding a 375-amino-acid protein contains seven regions of hydrophobic amino acids representing membrane-spanning domains of a heptahelix receptor, tentatively named CMKRL2. It shows nearly 30% overall identity with the high-affinity IL8 receptor and similar degree of homology with other chemoattractant receptors, including the coreceptors for HIV-1. Receptor expression was ubiquitous in brain and in peripheral tissue as well as in Burkitt's lymphoma (irrespective of EBV status). The receptor and the gene encoding the receptor are useful for detecting Burkitt's lymphoma.

Abstract: A full-length cDNA encoding a 375-amino-acid protein contains seven regions of hydrophobic amino acids representing membrane-spanning domains of a heptahelix receptor, tentatively named CMKRL2. It shows nearly 30% overall identity with the high-affinity IL8 receptor and similar degree of homology with other chemoattractant receptors, including the coreceptors for HIV-1. Receptor expression was ubiquitous in brain and in peripheral tissue as well as in Burkitt's lymphoma (irrespective of EBV status). The receptor and the gene encoding the receptor are useful for detecting Burkitt's lymphoma.

Abstract: The present invention provides a human leukotriene B4 receptor that acts as a coreceptor for HIV viruses, polynucleotides encoding the receptor, recombinant cells expressing the receptor, and antibodies against the receptor. The invention also provides methods of identifying drugs that can block viral infection of cells and methods of facilitating infection of cells with HIV viruses.